Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results
Go back to Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results| ALKERMES (NASDAQ: ALKS) | Delayed: 48.07 +2.05 (4.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.02 | 52 Week High | $80.71 | |||
| Open | $46.00 | 52 Week Low | $27.14 | |||
| Day High | $48.32 | P/E | 369.77 | |||
| Day Low | $45.47 | EPS | $0.13 | |||
| Volume | 2,451,763 | |||||
